Pharmajav.com

Transfersome  is a trademark registered by the  German  company IDEA AG, which refers to its  proprietary  drug delivery technology. The name means “carrying body” and is derived from the Latin word 'transferre', meaning 'to carry across', and the Greek word 'soma', meaning 'a body'. A  Transfersome  carrier is an  artificial vesicle  designed to exhibit the characteristics of a  cell vesicle  or a cell engaged in  exocytosis , and thus suitable for controlled and, potentially, targeted drug delivery. Discovery The term  Transfersome  and the underlying concept were introduced in 1991 by Gregor Cevc. Numerous groups have since been working with similar carriers, frequently using different names (e.g., elastic vesicle, flexible vesicle, Ethosome, etc.) to describe them. In a broader sense, a  Transfersome  is a highly adaptable, stress-responsive complex aggregate. The form preferred by researcher...

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, FDA provides scientific and regulatory advice needed to bring new therapies to market. The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. For this reason, CDER supports innovation and plays a key role in helping to advance new drug development. Each year, CDER approves a wide range of new drugs and biological products. Some of these products are innovative new products that never before have been used in clinical practice. Others are the same as, or related to, ...

Two decades after Indian Pharma started dabbling in new drug research, eight indigenously developed novel drugs are gearing up for late-stage human  trials.While  two new molecules are being developed by BioCon and Glenmark each, the others are contributed by  Dr.Reddy’s , Sun, Ranbaxy and Primal life sciences. Dr Reddy’s anti-diabetic drug, codenamed DRF 2593-307, was the first indigenously developed novel drug to enter phase-III trials, in August 2007. This is the penultimate round of testing on patients before marketing approval can be sought. Last year, two more compounds made it to this stage: Biocon’s oral insulin pill and Ranbaxy’s anti-malaria drug. A fourth drug, from Glenmark, to treat diarrhoea, is concurrently undergoing phase-II and phase-III trials. 1) IN-105 (Biocon) Therapy area:  Diabetes-insulin Status:  In phase-III human trials Target launch:  2011 in India; rest of the world by 2015 Global market size:  $13 ...